Mirscience Therapeutics
MirScience Therapeutics develops personalized RNA therapies targeting undruggable disease targets, focusing on diseases associated with longevity such as muscle atrophy, metabolic diseases like NASH, and cancer. Using their MIR-Discovery platform, they discover and develop microRNA molecules to create customized treatments, aiming to improve patients' quality of life and support healthy aging.
Industries
Nr. of Employees
small (1-50)
Mirscience Therapeutics
Rua Me. Cabrini, 462 – Vila Mariana, São Paulo – SP, 04020-040
Products
Preclinical microRNA candidate for muscle atrophy (preclinical)
A chemically engineered microRNA-derived oligonucleotide candidate developed to inhibit muscle atrophy pathways and promote muscle mass regeneration; demonstrated anti-atrophic and hypertrophic effects in preclinical studies.
Preclinical microRNA candidates for NASH (preclinical)
A set of preclinical oligonucleotide candidates addressing key NASH pathologies (inflammation, fibrosis, lipid metabolism, oxidative stress).
Preclinical microRNA candidate for muscle atrophy (preclinical)
A chemically engineered microRNA-derived oligonucleotide candidate developed to inhibit muscle atrophy pathways and promote muscle mass regeneration; demonstrated anti-atrophic and hypertrophic effects in preclinical studies.
Preclinical microRNA candidates for NASH (preclinical)
A set of preclinical oligonucleotide candidates addressing key NASH pathologies (inflammation, fibrosis, lipid metabolism, oxidative stress).
Services
End-to-end discovery and preclinical development of small RNA/oligonucleotide candidates targeting disease-associated genes, including target identification, molecule design, formulation, and in vivo efficacy testing.
Computational analysis and tool development for genomics and transcriptomics data to support target discovery and mechanism studies.
End-to-end discovery and preclinical development of small RNA/oligonucleotide candidates targeting disease-associated genes, including target identification, molecule design, formulation, and in vivo efficacy testing.
Computational analysis and tool development for genomics and transcriptomics data to support target discovery and mechanism studies.
Expertise Areas
- MicroRNA therapeutics
- Oligonucleotide chemistry and formulation
- Nanoparticle drug delivery (polymer and lipid platforms)
- Preclinical development and lead optimization
Key Technologies
- microRNA-based therapeutics
- Oligonucleotide chemical modification
- Lipid and polymer nanoparticle delivery
- RNA bioinformatics